Sponsors (22)
The bill improves privacy, independence, and safety for people with vision disabilities by requiring nonvisual access to home medical devices, but it may raise manufacturer costs, risk delays for some devices reaching patients, and impose additional workload on the FDA.
Patients with chronic conditions, seniors, and people with disabilities can manage care more independently and with fewer errors because nonvisual interfaces provide additional confirmation methods and allow safer at-home use.
People who are blind or have low vision gain private, independent access to home medical device interfaces that offer nonvisual interaction comparable in privacy and ease to sighted users.
Manufacturers and health systems benefit from clearer regulatory timelines, training, and guidance, reducing compliance uncertainty and helping plan for accessible product rollout.
Manufacturers may face additional design and testing costs and time, which could raise device prices for consumers or taxpayers and/or delay product releases.
Devices that cannot be feasibly modified may have delayed market entry while firms seek waivers or redesigns, delaying patient access to needed home medical technologies.
The FDA will need to allocate staff time and resources for rulemaking, training, consultations, and waiver reviews, which could divert agency capacity and slow regulatory reviews.
Based on analysis of 3 sections of legislative text.
Requires FDA to set nonvisual accessibility standards for user interfaces of many Class II/III medical devices so blind and low‑vision users can operate them as effectively as sighted users.
Introduced September 26, 2025 by Janice D. Schakowsky · Last progress September 26, 2025
Requires the FDA to set and enforce a nonvisual accessibility standard for user interfaces on many Class II and III medical devices so blind and low‑vision people can operate them as effectively and privately as sighted users. The rule covers devices with user interfaces that receive certain clearances or approvals after the rule's effective date, excluding devices intended only for health‑care‑provider or out‑of‑home use. The FDA must consult accessibility experts and blind/low‑vision individuals, propose the regulation within 1 year, finalize it within 2 years, and make the rule effective 1 year after publication. Manufacturers may request waivers, but only if they show clear and convincing evidence that compliance would cause a fundamental alteration or undue hardship.